GlassScriptPhysician profile
Brian A Harris
NPI 1275892002
$3,675.48
in general payments reported to CMS, 2019-2025
43 companies · $566 in 2025
The $566 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $205 · 2021: $220 · 2022: $420 · 2023: $640 · 2024: $518 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $462.10 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $429.39 | 2019-2025 | |
| Novo Nordisk INC | $305.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $263.47 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $251.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $251.19 | 2019-2025 | Airsupra |
| Pfizer INC. | $207.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.31 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.58 | 2019-2025 | Tradjenta, Synjardy, Jardiance |
| Novartis Pharmaceuticals Corporation | $95.89 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.06 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $69.43 | 2019-2024 | |
| Gilead Sciences, INC. | $67.38 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $65.83 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $60.00 | 2023-2024 | Rexulti |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.